Anticancer effects of phenoxazine derivatives combined with tumor necrosis factor-related apoptosis-inducing ligand on pancreatic cancer cell lines, KLM-1 and MIA-PaCa-2

Oncology Reports

Volumn 15, Issue 4, 2006, Pages 843-848

  Kato, Seiko ^a   Shirato, Ken ^b   Imaizumi, Kazuhiko ^b   Toyota, Hiroko ^a   Mizuguchi, Junichiro ^a   Odawara, Masato ^a   Che, Xiao Fang ^c   Akiyama, Shinichi ^c   Abe, Akihisa ^a   Tomoda, Akio ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Pancreatic cancer cells; Phenoxazine; Proliferation inhibition; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

2 AMINO 4,4ALPHA DIHYDRO 4ALPHA,7 DIMETHYL 3H PHENOXAZINE 3 ONE; 2-AMINO-4,4ALPHA-DIHYDRO-4ALPHA,7-DIMETHYL-3H-PHENOXAZINE-3-ONE; 3 AMINO 1,4A DIHYDRO 4A,8 DIMETHYL 2H PHENOXAZINE 2 ONE; 3 AMINOPHENOXAZONE; 3-AMINO-1,4A-DIHYDRO-4A,8-DIMETHYL-2H-PHENOXAZINE-2-ONE; 3-AMINOPHENOXAZONE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; MEMBRANE PROTEIN; OXAZINE DERIVATIVE; PHENOXAZINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR STRUCTURE; OXAZINES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746447990     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.4.843     Document Type: Article

References (34)

1. Bardeesy N and Depinho RA: Pancreatic cancer biology and genetics. Nat Rev 2: 897-909, 2002. (Pubitemid 37328891)
2. Gansauge S, Gansage F and Berger HG: Molecular oncology in pancreatic cancer. J Mol Med 74: 313-320, 1996. (Pubitemid 26194564)
3. Burris HA III, Moore MJ, Andersen J, Breen MR, Modiano MR, Rothenberg ML, Cripps MC, Portenoy RK, Storniolo AM, Tarassofff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
4. Hernandwez A, Wang QD, Schwartz SA and Evers BM: Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. Gastrointest Surg 5: 56-65, 2001. (Pubitemid 33651239)
5. Olsson A, Diaz T, Aquilar-Santelises M, Osterborg A, Celsing F, Jondal M and Osorio LM: Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 15: 1868-1877, 2001. (Pubitemid 33114993)
6. Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783, 2004. (Pubitemid 39545582)
7. Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B and Miki T: Enhanced sensitivity of bladder cancer cells to tumor necrosis factor released apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 165: 263-270, 2001.
8. Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M and Mizuguchi J: Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthopaed Res 21: 949-957, 2003. (Pubitemid 37045575)
9. Walczak H, Bouchon A, Stahl H and Krammer PH: Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2 or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res 60: 3051-3057, 2000. (Pubitemid 30395834)
10. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
11. Matsuzaki H, Schmied BM, Ulrich A, Standop J, Schneider MB, Batra SK, Picha KS and Pour PM: Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res 7: 407-414, 2001. (Pubitemid 32183046)
12. Hollstein U: Actinomycin. Chemistry and mechanism of action. Chem Rev 74: 625-652, 1974.
13. Hara K, Okamoto M, Aki T, Yagita H, Tanaka H, Mizukami Y, Nakamura H, Tomoda A, Hamasaki N and Kang D: Synergistic enhancement of TRAIL- and tumor necrosis factor α-induced cell death by a phenoxazine derivative. Mol Cancer Ther 4: 1121-1127, 2005. (Pubitemid 41079106)
14. Tomoda A: An improved method from the rapid preparation of a novel antitumor agent. Biorg Med Chem Lett 11: 1057-1058, 2002.
15. Shimizu S, Suzuki M, Tomoda A, Arai S, Taguchi H, Hanawa T and Kamiya S: Phenoxazine compounds produced by the reactions with bovine hemoglobin show antimicrobial activity against non-tuberculosis mycobacteria. Tohoku J Exp Med 203: 47-52, 2004. (Pubitemid 38832654)
16. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L and Bold RJ: Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110-2115, 2003. (Pubitemid 38030911)
17. Kimura Y, Kobari M, Yusa T, Sunamura M, Kimura M, Shimamura H and Matsuno S: Establishment of an experimental liver metastasis model by intraportal injection of a newly derived human pancreatic cancer cell line (KLM-1). Int J Pancreatol 20: 43-50, 1996. (Pubitemid 26292147)
18. Toyota H, Yanase N, Yoshimoto T, Moriyama M, Sudo T and Mizuguchi J: Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax. Cancer Lett 189: 221-230, 2003. (Pubitemid 35461998)
19. Andree HAM, Reutelingsperger CPM, Hauptomann R, Hecker HC, Hermens WT and Willems GM: Binding of vascular anticoagulant a (VACa) to planar phospholipid bilayers. J Biol Chem 265: 4925-4928, 1990.
20. Shimizu S, Suzuki M, Miyazawa K, Yokoyama T, Ohyashiki K, Miyazaki K, Abe A and Tomoda: Differentiation and apoptosis in human malignant melanoma G-361 cells induced by 2-aminophenoxazine-3-one. Oncol Rep 14: 41-46, 2005.
21. Jazirehi AR, Ng C-P, Gan X-H, Schiller G and Bonavida B: Adriamycin sensitizes the adriamycin-resistant 8226/Dox-40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res 7: 3874-3883, 2001. (Pubitemid 34044604)
22. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T and Suzuki A: Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32: 483-490, 2000.
23. Hawkins HK, Ericsson JL, Biberfield P and Trum BF: Lysosome and phagozome stability in lethal cell injury. Morphologic tracer studies in cell injury due to inhibition of energy metabolism, immune cytolysis and photosensitization. Am J Pathol 68: 255-258, 1972.
24. Mignotte B and Vayssiere JL: Mitochondria and apoptosis. Eur J Biochem 252: 1-15, 1998. (Pubitemid 28089952)
25. Kandel ES and Hay N: The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210-229, 1999.
26. Huang Z: Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19: 6627-6631.
27. Manion MK and Hockenbery DM: Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2: S105-S114, 2003.
28. Motohashi N, Mitscher LA and Myer R: Potential antitumor phenoxazines. Med Res Rev 11: 239-294, 1991.
29. Mori H, Honda K, Ishida R, Nohira T and Tomoda A: Antitumor activity of 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one against Meth A tumor transplanted into BALB/c mice. Anticancer Drugs 11: 653-657, 2000.
30. Shimamoto T, Tomoda A, Ishida R and Ohyashiki K: Antitumor effects of a novel phenoxazine derivative on human leukemia cell lines in vitro and in vivo. Clin Cancer Res 704: 704-708, 2001. (Pubitemid 32707997)
31. Nakada T, Isaka K, Nishi H, Osakabe Y, Shimamoto T, Ohyashiki K, Tomoda A and Takayama M: A novel phenoxazine derivative suppresses proliferation of human endometrial adenocarcinoma cell lines, inducing G2/M accumulation and apoptosis. Oncol Rep 10: 1171-1176, 2003.
32. Iwata A, Yamaguchi T, Sato K, Yoshitake N and Tomoda A: Suppression of proliferation of poliovirus and porcine parvovirus by novel phenoxazines, 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one and 3-amino-1,4α-dihydro-4α,8-dimethyl-2H-phenoxazine-2-one. Biol Pharm Bull 28: 905-907, 2005. (Pubitemid 40740665)
33. Uruma T, Yamaguchi H, Fukuda M, Kawakami H, Goto H, Kishimoto T, Yamamoto Y, Tomoda A and Kamiya S: Chlamydia pneumoniae growth inhibition in human monocyte cell line THP-1 cells and human epithelial HEp-2 cells by a novel phenoxazine derivative. J Med Microbiol (In press).
34. Gao S, Takano T, Sada K, He J, Noda C, Hori-Tamura N, Tomoda A and Yamamura H: A novel phenoxazine derivative suppresses surface IgM expression in DT40 B cell line. Br J Pharmacol 137: 749-755, 2002. (Pubitemid 35404173)